Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION337 in Dravet Syndrome
NCT07531745Phase 2Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- May 2026
- Primary completion
- Dec 2030
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of ION337 in Dravet syndrome, sponsored by Ionis Pharmaceuticals. Started May 2026; status: recruiting.
02
Drugs
ION337
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT07531745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07531745.